As Basilea enters 2026 with elevated operational momentum ahead of its FY25 results, we revisit key developments from 2025 and outline our expectations for the year ahead. Given Cresemba’s continued momentum, we expect global in-market sales to approach US$800m in FY26, driving an uplift in royalty
02 Feb 2026
Basilea Pharmaceutica:An emphatic start to 2026
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Basilea Pharmaceutica:An emphatic start to 2026
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
02 Feb 2026 -
Author:
Jyoti Prakash, CFA | Arron Aatkar, PhD -
Pages:
8 -
As Basilea enters 2026 with elevated operational momentum ahead of its FY25 results, we revisit key developments from 2025 and outline our expectations for the year ahead. Given Cresemba’s continued momentum, we expect global in-market sales to approach US$800m in FY26, driving an uplift in royalty